P-Values

Discover perspectives on the latest findings, biggest challenges and most exciting successes in our collective work.

At P-Values, you’ll find updates, perspective, insights and information from staff and partners working on the frontlines of research, advocacy and implementation. P-value is a statistical term for the probability that a trial result is reliable and not the outcome of chance. 

Featured

Blog Post

Global Health Watch: PEPFAR saved, PrEP pill advances to Ph3, NIH ad councils, IAS highlights

This week’s Global Health Watch highlights major developments in HIV prevention science and policy, spotlighted at the IAS 2025 conference in Kigali, Rwanda. From new WHO guidelines recommending injectable lenacapavir for PrEP to Merck’s once-monthly PrEP pill advancing to Phase 3 trials, the HIV prevention pipeline is expanding and evolving. All this amid an increasingly intense fight to protect global health funding.

Read more

Blog Post

Global Health Watch: Next steps in LEN for PrEP rollout, new UNAIDS report, reprieve for South Africa and the latest in AVAC’s lawsuit

This week the Global Fund and Gilead announced next steps in the process to rollout injectable lenacapavir, the new UNAIDS Global AIDS Update was released, and South Africa saw a partial reprieve for NIH-funded research. We also track AVAC’s court case against the foreign aid freeze and Congressional advocacy to protect NIH funding.

Read more

Filter by

Reset filters

P-Values

showing 1-10 of 1111

Global Health Watch: PEPFAR saved, PrEP pill advances to Ph3, NIH ad councils, IAS highlights

This week’s Global Health Watch highlights major developments in HIV prevention science and policy, spotlighted at the IAS 2025 conference in Kigali, Rwanda. From new WHO guidelines recommending injectable lenacapavir for PrEP to Merck’s once-monthly PrEP pill advancing to Phase 3 trials, the HIV prevention pipeline is expanding and evolving. All this amid an increasingly intense fight to protect global health funding.

July 2025

Day 1 at IAS 2025: Funding cliffs, epidemic-ending possibilities, and essential advocacy

The 13th International AIDS Society Conference on HIV Science, started this week amidst unifying calls to confront the collapse of US support for the HIV response with commitments to reimagine funding, research, development and programming aimed at sustaining progress toward ending the epidemic.

July 2025

Global Health Watch: Next steps in LEN for PrEP rollout, new UNAIDS report, reprieve for South Africa and the latest in AVAC’s lawsuit

This week the Global Fund and Gilead announced next steps in the process to rollout injectable lenacapavir, the new UNAIDS Global AIDS Update was released, and South Africa saw a partial reprieve for NIH-funded research. We also track AVAC’s court case against the foreign aid freeze and Congressional advocacy to protect NIH funding.

July 2025

IAS 2025 Conference

This year’s IAS Conference comes at a defining moment. Dramatic scientific advances are within reach, but global funding cuts are placing these innovations at risk. All this is jeopardizing the gains that communities, advocates, and researchers have fought for decades to achieve. Click for more, including our roadmap highlighting sessions where prevention and the larger issues of global health equity and sustainability are in the spotlight.

July 2025

Global Health Watch: Congress Passes “Big Bad Betrayal” Tax Bill, USAID Closes, Key Supreme Court Rulings

This week we saw Congress pass the President’s US domestic policy agenda that will rob approximately 17 million Americans of access to health care in order to provide tax cuts and workarounds for the rich. We also saw the official closure of USAID; restructuring of WHO leadership amid funding shortfalls; the US Supreme Court’s ruling preserving preventive care, including PrEP, and another ruling limiting federal courts’ ability to block presidential actions.

July 2025

Supreme Court Upholds ACA Preventive-Care Protections

AVAC welcomes today’s ruling affirming the constitutionality of the Affordable Care Act’s preventive services mandate, including coverage for HIV pre-exposure prophylaxis (PrEP) at no cost to patients. This decision represents a critical victory for public health, health equity, and the millions of people who rely on preventive services to stay healthy and safe.

June 2025

Global Health Watch: USAID in the Spotlight, Gavi Replenishment, Defense of the Rescissions Package and ACIP

This week brought major media attention to the devastating dismantling of USAID, even as the FDA’s approval of lenacapavir for PrEP signaled new hope in HIV prevention. At the same time, vaccines were under even greater assault as the US administration announced it would withdraw support from Gavi based on spurious claims, while the CDC’s Advisory Committee on Immunization Practices met for the first time since the Secretary of Health and Human Services fired leading vaccine experts and replaced them with a group of skeptics.

June 2025

The Cruel Irony of Prevention

It’s only been 22 weeks since the US President began dismantling US foreign aid. AVAC took a public stand against this attack on global health in our court case. All this comes at the same time as the introduction of a potentially transformational moment in HIV prevention — the introduction of injectable lenacapavir for PrEP.

Prevention Option:

Topic:

June 2025

Global Health Watch: LEN for PrEP approved by US FDA, South Africa’s HIV program in crisis, changes to oversight of NIH HIV guidelines

This week, we cover the US FDA approval of injectable lenacapavir (LEN) for PrEP, the “most transformative prevention product we’ve had in 44 years of this epidemic”, which demands urgent action if the remarkable science is translated into public health impact. Plus, updates on South Africa’s HIV program in crisis, oversight changes on NIH’s HIV clinical guidelines, and a court ruling halting illegal grant terminations.

June 2025

FDA Approves Injectable LEN for PrEP

This is the moment for all stakeholders to build on the momentum science. LEN has moved faster through regulatory review than any prevention product to date. Now it’s up to all of us to make sure that that progress translates into real, sustained impact on the epidemic, led by communities around the world. Let’s get to work.

June 2025

showing 1-10 of 1111

Explore More News and Communications

P-Values Blog

Discover perspectives on the latest findings, biggest challenges and most exciting successes in our collective work.

Advocates Network

AVAC’s email list for organization and individuals interested in timely updates and critical perspectives on developments in biomedical HIV prevention.

Weekly News Digest

A comprehensive round-up of HIV prevention media coverage and scientific publications.

PxPulse

Each month this podcast uses interviews, discussion and first-person reflections to explore vital topics confronting the field of HIV prevention research.

PxWire

PxWire is AVAC’s quarterly update on biomedical HIV prevention. Each issue highlights key developments, challenges and opportunities, and features a centerspread infographic that provides a visual tool for framing these issues.

Pandemic Watch

Pandemic Watch is a curated news digest on the latest pandemic prevention, preparedness, and response (PPPR) news and resources.

Press Releases

A collection of official statements from AVAC.

AVAC in the News

Media clippings featuring AVAC, its staff and close partners in the news media.